Category Archives: Molecular Medicine

Global Nuclear Medicine Molecular Imaging Technology Market Size, Status and Forecast 2020-2027

The data presented in the global Nuclear Medicine Molecular Imaging Technology market report is a compilation of data identified and collected from various sources. The scope of growth of the Nuclear Medicine Molecular Imaging Technology market during the forecast period is identified after analyzing different data sources. The report is a valuable guidance tool that can be used to increase the market share or to develop new products that can revolutionize the market growth. The analysis of the collected data also helps in providing an overview of the Nuclear Medicine Molecular Imaging Technology industry which further helps people make an informed choice. Latent growth factors that can manifest themselves during the forecast period are identified as they are key to the Nuclear Medicine Molecular Imaging Technology market growth. The Nuclear Medicine Molecular Imaging Technology report presents the data from the year 2020 to the year 2027 during the base period while forecasting the same during the forecast period for the year 2020 to the year 2027.

Get sample copy of Nuclear Medicine Molecular Imaging Technology Market [emailprotected] https://www.reportsandmarkets.com/sample-request/global-nuclear-medicine-molecular-imaging-technology-market-research-report-2020-2028?utm_source=3wnews&utm_medium=34

Top Key players: Toshiba, GE Healthcare, Segami Corporation, Philips Healthcare, Siemens Healthcare.

Our new sample is updated which correspond in new report showing impact of COVID-19 on Industry

The report scrutinizes different business approaches and frameworks that pave the way for success in businesses. The report used Porters five techniques for analyzing the Nuclear Medicine Molecular Imaging Technology Market; it also offers the examination of the global market. To make the report more potent and easy to understand, it consists of info graphics and diagrams. Furthermore, it has different policies and development plans which are presented in summary. It analyzes the technical barriers, other issues, and cost-effectiveness affecting the market.

Global Nuclear Medicine Molecular Imaging Technology Market Research Report 2020 carries in-depth case studies on the various countries which are involved in the Nuclear Medicine Molecular Imaging Technology market. The report is segmented according to usage wherever applicable and the report offers all this information for all major countries and associations. It offers an analysis of the technical barriers, other issues, and cost-effectiveness affecting the market. Important contents analyzed and discussed in the report include market size, operation situation, and current & future development trends of the market, market segments, business development, and consumption tendencies. Moreover, the report includes the list of major companies/competitors and their competition data that helps the user to determine their current position in the market and take corrective measures to maintain or increase their share holds.

What questions does the Nuclear Medicine Molecular Imaging Technology market report answer pertaining to the regional reach of the industry

A short overview of the Nuclear Medicine Molecular Imaging Technology market scope:

Reasons for Buying this Report

TABLE OF CONTENT:

Chapter 1: Nuclear Medicine Molecular Imaging Technology Market Overview

Chapter 2: Global Economic Impact on Industry

Chapter 3: Nuclear Medicine Molecular Imaging Technology Market Competition by Manufacturers

Chapter 4: Global Production, Revenue (Value) by Region

Chapter 5: Global Supply (Production), Consumption, Export, Import by Regions

Chapter 6: Global Production, Revenue (Value), Price Trend by Type

Chapter 7: Global Market Analysis by Application

Chapter 8: Manufacturing Cost Analysis

Chapter 9: Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 10: Marketing Strategy Analysis, Distributors/Traders

Chapter 11: Nuclear Medicine Molecular Imaging Technology Market Effect Factors Analysis

Chapter 12: Global Nuclear Medicine Molecular Imaging Technology Market Forecast to 2027

Get 10% Discount on Nuclear Medicine Molecular Imaging Technology Market @ https://www.reportsandmarkets.com/check-discount/global-nuclear-medicine-molecular-imaging-technology-market-research-report-2020-2028?utm_source=3wnews&utm_medium=34

About Us:

Reports And Markets is part of the Algoro Research Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Are you mastering your market? Do you know what the market potential is for your product, who the market players are and what the growth forecast is? We offer standard global, regional or country specific market research studies for almost every market you can imagine.

Contact Us:

Sanjay Jain

Manager Partner Relations & International Marketing

http://www.reportsandmarkets.com

Ph: +1-352-353-0818 (US)

Read more here:
COVID-19 Impact on Nuclear Medicine Molecular Imaging Technology Market Forecast to 2027 Toshiba, GE Healthcare, Segami Corporation, Philips...

The federal governments Operation Warp Speed vaccine program, with its emphasis on quick production and testing of experimental coronavirus vaccines, is fueling fears already stirred up by vaccine skeptics, two experts said Friday.

The approach itself is not unreasonable, said Dr. Peter Hotez, dean of the National School of Tropical Medicine and professor of pediatrics and molecular virology and microbiology at Baylor College of Medicine. But the way its being communicated is scaring people, he told CNN.

The way the message is coming out of Operation Warp Speed creates a lot of chaos and confusion. And it is enabling the anti-vaccine movement, Hotez said.

A White House coronavirus task force source told CNN earlier this week that the Trump Administrations Warp Speed program had chosen five companies mostly likely to produce a Covid-19 vaccine whittled down from 14 last month when Operation Warp Speed was launched.

Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, says he expects up to 100,000 doses of one vaccine, made by biotech company Moderna, to be available by the end of the year, ready to be rolled out if it is shown to work safely to protect people against coronavirus infection in clinical trials that are now under way.

He has said one of the candidates could be ready as early as January. That is a highly accelerated schedule, as vaccines typically take years to produce.

We think we are going to have a vaccine in the pretty near future, and if we do, we are going to really be a big step ahead, Trump said last month.

The way they are messaging it is a little frightening because they make a point of saying how quickly it is being done, said Dr. Paul Offit, director of the Vaccine Education Center and professor of pediatrics at Childrens Hospital of Philadelphia. It makes people think there are steps being skipped.

Hotez and Offit should know. They have both spent years fighting an organized anti-vaccination effort, and trying to educate people who have doubts and fears about vaccines. Both have written books about vaccine safety. Hotez wrote Vaccines Did Not Cause Rachels Autism, about his daughter, and Offit has written several books, including Deadly Choices: How the Anti-Vaccine Movement Threatens Us All.

What does the anti-vaccine lobby allege? Hotez asked. They say we rush vaccines, that we dont adequately test them for safety, and that there is this conspiratorial relationship between Big Pharma and the government.

And then vaccine makers send out news releases trumpeting incremental successes. Last month, Moderna, the US biotech company heavily promoted by the White House and the National Institutes of Health, announced promising early results, sending its share price up 30%. At the same time, two top executives sold $30 million worth of shares.

Lorence Kim, Modernas chief financial officer, exercised 241,000 options for $3 million, filings show. He then immediately sold them for $19.8 million, creating a profit of $16.8 million.

The next day, Tal Zaks, Modernas chief medical officer, spent $1.5 million to exercise options. He immediately sold the shares for $9.77 million, triggering a profit of $8.2 million.

It was all legal, but looked bad, Hotez said.

They are shooting themselves in the foot, he said.

On Thursday, National Institutes of Health director Dr. Francis Collins said he feared vaccine skepticism would make people unwilling to get the coronavirus vaccine. He also said the messaging would be important.

Offit worries that companies and the federal government may actually be tempted to skip safety steps in the rush to protect people from coronavirus. That wouldnt make the vaccine skeptics right, but it could be dangerous and further erode credibility.

You have a president who said hydroxychloroquine was going to work. He said, I heard really good things about it and how could it hurt, Offit said. None of that was right. First, it didnt work, and second, it did hurt. It has cardiac toxicity.

Offit worries something even more damaging could happen with a vaccine. Currently the federal government is helping develop both vaccines and drugs to fight coronavirus.

Do I think this administration has the capacity to perturb the process? asked Offit. Yes, I do.

So far, Offit sees nothing that has gone wrong with any of the vaccines in development. He doesnt see any indication that safety is being sacrificed.

But its clear to him why the administration would choose five vaccines to focus on.

Its because they are the fastest to make, Offit said. All use biotechnology approaches to make vaccines using genetic sequences, as opposed to the tried-and true but slow approach of using a whole virus that has been either weakened or killed.

As long as the phase 3 trials are done and respected, I think the speed we are witnessing will be fine, Offit said. But the phase 3 trials, one of which is penciled in to be done in 30,000 volunteers later this year, must be taken to the end to ensure that any rare side effects from vaccination will become visible.

That is the part that cannot be skipped, Offit said.

Continue reading here:
'Operation Warp Speed' is fueling vaccine fears, two top experts worry - KEYT

Molecular Microbiology Market

Los Angeles, United State, June 7th, 2020, The global Molecular Microbiology market is carefully researched in the report while largely concentrating on top players and their business tactics, geographical expansion, market segments, competitive landscape, manufacturing, and pricing and cost structures. Each section of the research study is specially prepared to explore key aspects of the global Molecular Microbiology market. For instance, the market dynamics section digs deep into the drivers, restraints, trends, and opportunities of the global Molecular Microbiology Market. With qualitative and quantitative analysis, we help you with thorough and comprehensive research on the global Molecular Microbiology market. We have also focused on SWOT, PESTLE, and Porters Five Forces analyses of the global Molecular Microbiology market.

Some of the important Key Player operating in the Report Are: Roche, Qiagen, Illumina, Abbott, Hologic, BioMerieux, Danaher (Cepheid), Myriad Genetics, DAAN Gene, Agilent, Genomic Health, BD, Foundation Medicine

Request a Sample of this report at: https://www.qyresearch.com/sample-form/form/1086170/global-molecular-microbiology-market

Segmental Analysis

The report has classified the global Molecular Microbiology industry into segments including product type and application. Every segment is evaluated based on growth rate and share. Besides, the analysts have studied the potential regions that may prove rewarding for the Molecular Microbiology manufacturers in the coming years. The regional analysis includes reliable predictions on value and volume, thereby helping market players to gain deep insights into the overall Molecular Microbiology industry.

Segmentation by Type:

Quantitative PCR Detection Diagnostic Kits, Pathogenic Microorganisms Diagnostic Kits

Segmentation by application:

Human, Veterinary

Competitive Landscape

It is important for every market participant to be familiar with the competitive scenario in the global Molecular Microbiology industry. In order to fulfil the requirements, the industry analysts have evaluated the strategic activities of the competitors to help the key players strengthen their foothold in the market and increase their competitiveness.

Key companies operating in the global Molecular Microbiology market include: Roche, Qiagen, Illumina, Abbott, Hologic, BioMerieux, Danaher (Cepheid), Myriad Genetics, DAAN Gene, Agilent, Genomic Health, BD, Foundation Medicine

Regions Covered in the Global Molecular Microbiology Market:

Key questions answered in the report:

Enquire For Customization In the Report: https://www.qyresearch.com/customize-request/form/1086170/global-molecular-microbiology-market

Strategic Points Covered in TOC:

Table of Contents 1 Molecular Microbiology Market Overview1.1 Molecular Microbiology Product Overview1.2 Molecular Microbiology Market Segment by Type1.2.1 Quantitative PCR Detection Diagnostic Kits1.2.2 Pathogenic Microorganisms Diagnostic Kits1.3 Global Molecular Microbiology Market Size by Type1.3.1 Global Molecular Microbiology Sales and Growth by Type1.3.2 Global Molecular Microbiology Sales and Market Share by Type (2014-2019)1.3.3 Global Molecular Microbiology Revenue and Market Share by Type (2014-2019)1.3.4 Global Molecular Microbiology Price by Type (2014-2019) 2 Global Molecular Microbiology Market Competition by Company2.1 Global Molecular Microbiology Sales and Market Share by Company (2014-2019)2.2 Global Molecular Microbiology Revenue and Share by Company (2014-2019)2.3 Global Molecular Microbiology Price by Company (2014-2019)2.4 Global Top Players Molecular Microbiology Manufacturing Base Distribution, Sales Area, Product Types2.5 Molecular Microbiology Market Competitive Situation and Trends2.5.1 Molecular Microbiology Market Concentration Rate2.5.2 Global Molecular Microbiology Market Share of Top 5 and Top 10 Players2.5.3 Mergers & Acquisitions, Expansion 3 Molecular Microbiology Company Profiles and Sales Data3.1 Roche3.1.1 Company Basic Information, Manufacturing Base and Competitors3.1.2 Molecular Microbiology Product Category, Application and Specification3.1.3 Roche Molecular Microbiology Sales, Revenue, Price and Gross Margin(2014-2019)3.1.4 Main Business Overview3.2 Qiagen3.2.1 Company Basic Information, Manufacturing Base and Competitors3.2.2 Molecular Microbiology Product Category, Application and Specification3.2.3 Qiagen Molecular Microbiology Sales, Revenue, Price and Gross Margin(2014-2019)3.2.4 Main Business Overview3.3 Illumina3.3.1 Company Basic Information, Manufacturing Base and Competitors3.3.2 Molecular Microbiology Product Category, Application and Specification3.3.3 Illumina Molecular Microbiology Sales, Revenue, Price and Gross Margin(2014-2019)3.3.4 Main Business Overview3.4 Abbott3.4.1 Company Basic Information, Manufacturing Base and Competitors3.4.2 Molecular Microbiology Product Category, Application and Specification3.4.3 Abbott Molecular Microbiology Sales, Revenue, Price and Gross Margin(2014-2019)3.4.4 Main Business Overview3.5 Hologic3.5.1 Company Basic Information, Manufacturing Base and Competitors3.5.2 Molecular Microbiology Product Category, Application and Specification3.5.3 Hologic Molecular Microbiology Sales, Revenue, Price and Gross Margin(2014-2019)3.5.4 Main Business Overview3.6 BioMerieux3.6.1 Company Basic Information, Manufacturing Base and Competitors3.6.2 Molecular Microbiology Product Category, Application and Specification3.6.3 BioMerieux Molecular Microbiology Sales, Revenue, Price and Gross Margin(2014-2019)3.6.4 Main Business Overview3.7 Danaher (Cepheid)3.7.1 Company Basic Information, Manufacturing Base and Competitors3.7.2 Molecular Microbiology Product Category, Application and Specification3.7.3 Danaher (Cepheid) Molecular Microbiology Sales, Revenue, Price and Gross Margin(2014-2019)3.7.4 Main Business Overview3.8 Myriad Genetics3.8.1 Company Basic Information, Manufacturing Base and Competitors3.8.2 Molecular Microbiology Product Category, Application and Specification3.8.3 Myriad Genetics Molecular Microbiology Sales, Revenue, Price and Gross Margin(2014-2019)3.8.4 Main Business Overview3.9 DAAN Gene3.9.1 Company Basic Information, Manufacturing Base and Competitors3.9.2 Molecular Microbiology Product Category, Application and Specification3.9.3 DAAN Gene Molecular Microbiology Sales, Revenue, Price and Gross Margin(2014-2019)3.9.4 Main Business Overview3.10 Agilent3.10.1 Company Basic Information, Manufacturing Base and Competitors3.10.2 Molecular Microbiology Product Category, Application and Specification3.10.3 Agilent Molecular Microbiology Sales, Revenue, Price and Gross Margin(2014-2019)3.10.4 Main Business Overview3.11 Genomic Health3.12 BD3.13 Foundation Medicine 4 Molecular Microbiology Market Status and Outlook by Regions4.1 Global Market Status and Outlook by Regions4.1.1 Global Molecular Microbiology Market Size and CAGR by Regions4.1.2 North America4.1.3 Asia-Pacific4.1.4 Europe4.1.5 South America4.1.6 Middle East and Africa4.2 Global Molecular Microbiology Sales and Revenue by Regions4.2.1 Global Molecular Microbiology Sales and Market Share by Regions (2014-2019)4.2.2 Global Molecular Microbiology Revenue and Market Share by Regions (2014-2019)4.2.3 Global Molecular Microbiology Sales, Revenue, Price and Gross Margin (2014-2019)4.3 North America Molecular Microbiology Sales, Revenue, Price and Gross Margin4.3.1 United States4.3.2 Canada4.3.3 Mexico4.4 Europe Molecular Microbiology Sales, Revenue, Price and Gross Margin4.4.1 Germany4.4.2 UK4.4.3 France4.4.4 Italy4.4.5 Russia4.4.6 Turkey4.5 Asia-Pacific Molecular Microbiology Sales, Revenue, Price and Gross Margin4.5.1 China4.5.2 Japan4.5.3 Korea4.5.4 Southeast Asia4.5.4.1 Indonesia4.5.4.2 Thailand4.5.4.3 Malaysia4.5.4.4 Philippines4.5.4.5 Vietnam4.5.5 India4.5.6 Australia4.6 South America Molecular Microbiology Sales, Revenue, Price and Gross Margin4.6.1 Brazil4.7 Middle East and Africa Molecular Microbiology Sales, Revenue, Price and Gross Margin4.7.1 Egypt4.7.2 GCC Countries 5 Molecular Microbiology Application/End Users5.1 Molecular Microbiology Segment by Application5.1.1 Human5.1.2 Veterinary5.2 Global Molecular Microbiology Product Segment by Application5.2.1 Global Molecular Microbiology Sales by Application5.2.2 Global Molecular Microbiology Sales and Market Share by Application (2014-2019) 6 Global Molecular Microbiology Market Forecast6.1 Global Molecular Microbiology Sales, Revenue Forecast (2019-2025)6.1.1 Global Molecular Microbiology Sales and Growth Rate Forecast (2019-2025)6.1.1 Global Molecular Microbiology Revenue and Growth Rate Forecast (2019-2025)6.2 Global Molecular Microbiology Forecast by Regions6.2.1 North America Molecular Microbiology Sales and Revenue Forecast (2019-2025)6.2.2 Europe Molecular Microbiology Sales and Revenue Forecast (2019-2025)6.2.3 Asia-Pacific Molecular Microbiology Sales and Revenue Forecast (2019-2025)6.2.3.1 China6.2.3.2 Japan6.2.3.3 Korea6.2.3.4 Southeast Asia6.2.3.5 India6.2.3.6 Australia6.2.4 South America Molecular Microbiology Sales and Revenue Forecast (2019-2025)6.2.5 Middle East and Africa Molecular Microbiology Sales and Revenue Forecast (2019-2025)6.2.5.1 Egypt6.2.5.2 GCC Countries6.3 Molecular Microbiology Forecast by Type6.3.1 Global Molecular Microbiology Sales and Revenue Forecast by Type (2019-2025)6.3.2 Quantitative PCR Detection Diagnostic Kits Gowth Forecast6.3.3 Pathogenic Microorganisms Diagnostic Kits Gowth Forecast6.4 Molecular Microbiology Forecast by Application6.4.1 Global Molecular Microbiology Sales Forecast by Application (2019-2025)6.4.2 Global Molecular Microbiology Forecast in Human6.4.3 Global Molecular Microbiology Forecast in Veterinary 7 Molecular Microbiology Upstream Raw Materials7.1 Molecular Microbiology Key Raw Materials7.1.1 Key Raw Materials7.1.2 Key Raw Materials Price7.1.3 Raw Materials Key Suppliers7.2 Manufacturing Cost Structure7.2.1 Raw Materials7.2.2 Labor Cost7.2.3 Manufacturing Expenses7.3 Molecular Microbiology Industrial Chain Analysis 8 Marketing Strategy Analysis, Distributors8.1 Marketing Channel8.1.1 Direct Marketing8.1.2 Indirect Marketing8.1.3 Marketing Channel Development Trend8.2 Distributors8.3 Downstream Customers 9 Research Findings and Conclusion AppendixMethodology/Research ApproachResearch Programs/DesignMarket Size EstimationMarket Breakdown and Data TriangulationData SourceSecondary SourcesPrimary SourcesDisclaimer

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from the huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become a brand of quality assurance in the consulting industry.

Read more from the original source:
Molecular Microbiology Market Statistics, Facts and Figures, Investment Trends, Key Players and Forecast by 2026 - Weekly Wall

Precision medicine (PM) is an approach to patient care that allows doctors to select treatments that are most likely to help patients based on a genetic understanding of their disease. Personalized nanomedicine involving individualized drug selection and dosage profiling in combination with clinical and molecular biomarkers can ensure the maximal efficacy and safety of the treatment. The major hindrance toward the development of such therapies is the handling of the Big Data, to keep the databases updated. Robust automated data mining tools are being developed to extract information regarding genes, variations, and their association with diseases. Phenotyping, an integral part of PM, is aimed at translating the data generated at cellular and molecular levels into clinically relevant information.Precision Medicine Moves Care from Population-Based Protocols to Truly Individualized Medicine as President of the US announced the Precision Medicine Initiative in his 2015 State of the Union address. Under the initiative, medical care would transition from a one-size-fits-all approach to an individualized approach, in which data on each patients genomic makeup, environment, and lifestyle (the exposome) helps medical professionals tailor treatment and prevention strategies. To achieve the Precision Medicine Initiative mission statement, to enable a new era of medicine through research, technology, and policies that empower patients, researchers, and providers to work together toward development of individualized care, researchers and clinicians need vast and varied amounts of data and the technology to ensure that data is widely accessible and usable.

Browse Complete Report with TOC https://univdatos.com/report/precision-medicine-market-current-analysis-and-forecast-2020-2026

Insights Presented in the Report

Based on technology type, the market is fragmented into big data analytics, bioinformatics, gene sequencing, drug discovery, companion diagnostics, and others.Recent technological and analytical advances in genomics, have now made it possible to rapidly identify and interpret the genetic variation underlying a single patients disease, thereby providing a window into patient-specific mechanisms that cause or contribute to disease, which could ultimately enable the precise targeting of these mechanisms

Based on the market segment by application type, the market is segmented into oncology, respiratory diseases, central nervous system disorders, immunology, genetic diseases and others. With the advent of precision medicine, cancer treatment is moving from a paradigm in which treatment decision isprimarily based on tumor location and histology followed by molecular information to a new paradigm whereby treatment decisions will be primarily based on molecular information followed by histology and tumor location

Based on the market segment by end-user, the market is fragmented into hospitals & clinics, pharmaceuticals, diagnostic companies, Healthcare-IT firms and others. The precision medicine suppliers that understand technology and the goals of value-based healthcare can create value in the precision medicine value-chain by offering value-based solutions and platforms to interpret and connect data points. There are a number of technology companies who work in the field of precision medicine and more will be founded in the years to come

For better understanding on the market dynamics of Precision Medicine market, detailed analysis was conducted for different countries in the region including North America (United States, Canada, Mexico and Rest of North America), Europe (Germany, UK, France, Italy, Spain and Rest of Europe), Asia-Pacific (China, Japan, Australia, India and Rest of APAC), and Rest of World

Some of the major players operating in the market includeHoffmann-La Roche, Medtronic, Qiagen, Illumina, Abbott Laboratories, GE Healthcare, NanoString Technologies, bioMrieux SA, Danaher Corporation, and AstraZeneca

Request for Sample of the report https://univdatos.com/request_form/form/286

Reasons to buy this report:

The study includes market sizing and forecasting analysis validated by authenticated key industry experts

The report presents a quick review of overall industry performance at one glance

The report covers in-depth analysis of prominent industry peers with a primary focus on key business financials, product portfolio, expansion strategies, and recent developments

Detailed examination of drivers, restraints, key trends and opportunities prevailing in the industry.

Examination of industry attractiveness with the help of Porters Five Forces analysis

The study comprehensively covers the market across different segments

Deep dive regional level analysis of the industry

Feel free to contact us for any queries https://univdatos.com/request_form/form/286

Customization Options:

Precision MedicineMarket can further be customized as per the requirement or any other market segment. Besides this, UMI understands that you may have your own business needs, hence feel free to connect with us to get a report that completely suits your requirements.

About us:

UnivDatos Market Insights (UMI), is a passionate market research firm and a subsidiary of Universal Data Solutions. We believe in delivering insights through Market Intelligence Reports, Customized Business Research, and Primary Research. We are a diverse group of some of the most talented people in the research landscape, who with their collective experience, help us drive our machine and creatively solve every business challenge of millennial organizations. Our team comprises of accomplished professionals from leading consulting environments and serve some of the significant Fortune 500 companies around the world.

Contact us:

UnivDatos Market Insights (UMI)

Email: [emailprotected]

Web: https://univdatos.com

Ph: +91 7838604911

Read the original post:
Precision Medicine Market Industry Analysis, Size, Share, Growth, Trends, and Forecast 2020-2026 - 3rd Watch News

Infectious disease expert Michael Osterholm talks about our lack of national plan and when we will have testing available. USA TODAY

The nations slow, fumbling response to the pandemic spawned a new mandate: Get tests to the public as quickly as possible.

Lack of testing for COVID-19 in February and March left the nation unprepared for a virus that raced ahead of the ability to detect it. The Trump administration sought to accelerate testing by relaxing bureaucratic red tape and spending billions to bolster labs, drive-thru clinics, retail testing sites and rapid point-of-care testing at doctor's offices.

With public and private labs now performing more than 400,000 tests most days a figure the U.S. Department of Health and Human Services projects will more than double by late summersome question whether accelerated testing comes at a cost.A strategy built on the quantity of tests does not account for nuances and limitations, lacks coordination and wastes limited testing supplies.

I get concerned that in the rush to get testing out, were compromising quality, said Dr. Eric Blank, chief program officer of the Association of Public Health Laboratories. Youve got to have quality in order to make informed decisions.

Testsinform governors and public health officials on when it's safe to resumedaily activities such as going to restaurants, social gatherings or sporting events. School boards must decide when and how students can return to classrooms. Employers want to safely reopen offices.

President Donald Trump has repeatedly touted the U.S. as the worlds testing leader, setting a goal of 40 to 50 million tests each month by September. However, the Trump administration wants states to develop their own testing strategies to slow the COVID-19 pandemic, which has so far infectednearly 1.9million U.S. residents and killed more than 108,000.

Test accuracy varies and can give individuals who falsely test negative for the virus an unwarrantedsense of security. Labs are operating around the clock to keep up with demand from the expectation that any person, at any time, can get a test. And with three types of tests from dozens of test-kit makers, doctors and patients are confused by when and what type of test they might need.

Dr. Robert Redfield, director of the Centers for Disease Control and Prevention, acknowledged Thursday that better testing involves more than increasing the number of tests.

"I dont want to get into the number of tests because I dont think thats thereal issue," Redfield told a Congressional committee Thursday. "Its how testing is used and whats the consequence."

Others say its not the numbers of tests that are important. Rather, its how tests are deployed and coordinated to gather meaningful information about the pandemic.

Dr. Michael Osterholm, director of the Center for Infectious Disease Research and Policy at the University of Minnesota, said the nation needs a smarter testing system. CIDRAP,a public health and infectious disease research group, has asked HHSSecretary Alex Azar to appoint a panel of national experts to address testing objectives.

Michael T. Osterholm is director of the Center for Infectious Disease Research and Policy at the University of Minnesota.(Photo: Tim Rummelhoff, CIDRAP, University of Minnesota)

Meanwhile, the Trump administration has stressed states need to implement their owntesting strategies. On April 27, the administration released a testing blueprint, and reiterated states' testing responsibilities in aMay 24 report to Congress called the COVID-19 Strategic Testing Plan.

The administration set a goal of states testing 2% of their population, but the report showed statetesting rates varied widely.

More: Antibody tests were supposed to help guide reopening plans. They've brought more confusion than clarity.

More: COVID-19 expert: Coronavirus will rage 'until it infects everybody it possibly can'

More: '50 states and 50 different approaches:' States scramble to hire COVID-19 contact tracers

Osterholm said focusing on the quantity of tests might not yield the best results. For example, a drive-thru clinic might test several hundred individuals with no signs of the virus, while people with symptoms cant access testing.

Far too many states that have focused on, 'Just how many can I get tested today?' said Osterholm, an infectious-disease doctor.

The key is to develop a system that gets the right test to the right person atthe right time, he said.

If two states have the same population, one state might test 5,000 per day, the other 10,000 people per day, and the state at 5,000 per day might be doing a much better job, he said. Its all about how smart they are testing.

Infectious disease doctors say testing iscritical because the virus will continue to spread until an effective vaccine is available. Without a vaccine, the virus might spread beyond 5% now infected to60% to 70%of the population needed to reach herd immunity,Osterholm said.

"So with all the pain, suffering, death andeconomic disruption thats occurred, weve got a long ways to go yet," he said.

Until then, public health labs that provide surveillance testing will play a vitalrole in tracking the virus and slowing its spread.

In February, the CDC sought to establish a tracking system in six cities to track whether the virus had spread beyond initial travelers returning from China. The effort stalled, leaving a patchwork system tracking spread in communities.

Private labs are testing. Large retailers such as Walmart and CVS are making it convenient. And doctors and individuals get the results.

But theres no centralized effort to collect information in uniform way, said Dr. Farzad Mostashari, CEO of Aledade Inc. and a former senior official with HHS.

The most obvious failure is we dont have any consistent testing of a consistent population that we can track over time in different places, said Mostashari, also a former assistant commissioner of the New York City Department of Public Health.

Such uniform data could answer key questions: What is the average time to diagnose a patient from the time symptoms appear?How can contact tracers get timely information needed to slow the spread?

We are doing mass testing at Walmart and were celebrating how great it is, said Mostashari. Even though we are doing magnitudes more tests, we are not getting meaning. We are not getting answers.

Accurate, public health data would allow decision-makers to react quickly as states and cities reopen. Contact tracers can inform infected individuals to isolate and quickly notifytheir contacts to monitor for symptoms.

What you really want to know is who has it now and is capable of giving to someone else today, said Dr. Robert Wachter, chair of the University of California, San Francisco Department of Medicine.

UCSF is testing thousands of patients, even those without symptoms, to get a snapshot of the pathogen's community spread. The academic hospital is conducting surveillance testing in two San Francisco communities: Mission District, a neighborhood with a large Latino community and a higher prevalence of COVID-19, and Bayview Hunters-Point, which has a large African American population.

In the absence of a federal testing strategy, the hospital is trying to build data and learn more about how the virus is spreading. Suchinformation will help discern when the virus is heating up and allow local leaders to adapt.

That is kind of the super power of this virus you might have it and be capable of transmitting it and you feel fine, Wachter said.

There are three types of coronavirus tests molecular, antigen and serology each with varying degrees of accuracy.

The molecular and antigen tests detect whether a person has an active case of COVID-19, the disease caused by the SARS CoV-2 virus.The serology tests detect whether a person has been previously infected with thevirus and has developed antibodies to fend it off.

Given that there are three types of tests with varying degrees of accuracy, consumers and even some doctors might be confused, experts say.

People look at a test as a test, like turning a light switch on and off, Osterholm said. Its not that simple.

One measure of test accuracy is sensitivity: how often a test correctly identifies a person has the virus that causes COVID-19. Another measure is specificity: whetherthe test accurately shows when the person does not have the virus.

Doctors need to evaluate characteristics of each test and apply reasoning when interpreting results, Wachter said.For example, a doctor should consider a patient's clinical symptoms and community trends of the virus.

Each test has different flaws, said Wachter.

Molecular PCR tests, which require a mucus sample from the nose or throat, typically have low levels of false positives. So when a molecular test for the virus is positive, its a safe assumption the test is right. However, when a person tests negative for the virus, that does not mean they are disease-free.

Timing is critical. A person might not immediately develop symptoms, so they dont get tested. There is a limited window of five to seven days when the test will detect a person has coronavirus. Or an inadequate sample might fail to pick up enough genetic material to identify the virus.

The test doesnt get it wrong that often when the test is positive, Wachter said. Whereas it does get it wrong reasonably often, when the result is negative.

Antibody tests are blood tests that detect whether someone was previously infected. Public health officials raised concerns about test accuracy after the Food and Drug Administration allowed test makers to validate their own data before marketing to consumers. Following complaints, the FDA moved to tighten oversight of these tests.

By September,as many as 25 million tests will be rapid "point of care" tests at clinics, doctor's offices, nursing homes and urgent care centers that deliver immediate results, according to theCOVID-19 Strategic Testing Plan.

An example of this type of test is the Abbott ID Now testthat can deliver results within 15 minutes. The FDAissued an alert about "early data that suggest potential inaccurate results" from the toaster-sized device following a small study from New York University.

But Abbott questioned the NYU study and released its own data from an interim study that found the test identified the virus 94.7% of the time.Test results depend on factors such aspatient selection,specimen collection, handling, storage and transport, Abbott said.

Wachter said the accuracy of the Abbott ID Now test, used by the White House, is an example of decision employers and doctors must consider when evaluating a test. The White House usesthe tests to decide who can come into contact with Trump, who choose not to wear a mask.

Its important to get correct test results so infected individuals can self-isolate and not pass the virus to others. And public health officials can contact those who were potentially exposed to the infected individual.

Still, the push to get rapid testing to the public might compromise quality, Blank said.

"If you want something rapid, if you want something quick, if you want something accessible, you are going to have to give something up," he said. "But the question I have is how much quality can you afford to give up?

Blank, of APHL, said public health laboratories are struggling to keep up with testing demands of the pandemic.

State and local public health laboratories are accustomed to running full tilt for two to three weeks to respond to local or regional outbreaks. With coronavirus, public health labs have been running extra shifts seven days a week since February.

We have heard consistently that they are holding upbut barely, Blank said.

Large commercial labs are accustomed to running round-the-clock shifts with testing platforms that can quickly process samples. Public health labs dont have the staffing and equipment to sustain those levels.

Redfield said Thursday he's "personally saddened" only a handful of state labs have "the capability to do what needs to be done." He praised New York's Wadsworth Center lab for developing rapid testing on a "high-throughputplatform," not the "slow platform we have for flu."

The CDC sent $10.25 billionto states to invest in public health response. Each state must submit detailed testingplans and benchmarks to the CDC the first report was due May 31, and a second report is dueJune 15.

State labs also needsustained funding to hire trained labs workers to replenish an aging and stressed workforce.

Theyve never come out and said we are at the breaking point, Blank said. I never expect them to say that. But I have been a lab director and I suspect they are close to the breaking point.

Follow the reporter on Twitter@kalltucker or email him at alltuck@usatoday.com

Read or Share this story: https://www.usatoday.com/story/news/health/2020/06/06/coronavirus-test-covid-19-tests-increase-plan-lacking/3138440001/

Originally posted here:
COVID testing: More isn't necessarily better, 'its all about how smart they are testing' - USA TODAY

Ali Shilatifard

A pandemicespecially one caused by a mysterious or newly discovered infectious agentengenders a stark reminder that supporting fundamental research has been a prudent investment of public funds. Fundamental molecular research plays an essential role in the clinic to decipher infectious processes, develop therapeutic strategies, and guide physicians, nurses, and other hospital employees in implementing the most effective application of new knowledge. As the world begins the process of healing from the medical, social, and economic effects of coronavirus disease 2019 (COVID-19), public health is at the forefront of decision-making by lawmakers at both the federal and state levels. Daily news conferences and press releases illustrate the importance of scientists and physicians as major partners in pandemic task forces, guiding politicians in health policy decision-making. Basic molecular research plays a crucial role in helping the world overcome the current pandemic and prepare for the next one.

The first application of fundamental molecular research to COVID-19 was rapid sequencing of the SARS-CoV-2 RNA genome using a process known as next-generation sequencing (NGS). These data immediately delivered the scientific and clinical communities with insight into the singular properties of this coronavirus strain. NGS can provide billions of DNA reads in a single day, a process that was unfathomable only 15 years ago. Now an essential and nearly ubiquitous technology, NGS evolved through the research of biochemists, molecular biologists, and engineers who were supported by grants from publicly funded institutions such as the U.S. National Institutes of Health (NIH), National Cancer Institute (NCI), and their counterparts across the globe. The second major application of fundamental molecular research to COVID-19 was the development of an assay to identify infected individuals. The method of choice for high-sensitivity detection of the virus in people is reverse transcription followed by polymerase chain reaction (RT-PCR), which takes advantage of the viral genome sequence provided by NGS. A key component of this assay is the reverse transcriptase RNA-dependent DNA polymerase, which converts the viral RNA genome into a DNA molecule that can be amplified and detected. This enzyme was a Nobel prize winning discovery by NIH/NCI-supported researchers Howard Temin and David Baltimore. Although the PCR amplification methods and instruments were finalized in the private sector, much of the enzymology and nucleic acid chemistry that spurred PCR development was based on publicly funded fundamental molecular research.

Developing COVID-19 therapeutics requires an in-depth understanding of molecular processes involved in the viral life cycle. Antiviral therapies are needed to treat patients with mild to moderate symptoms. Additional therapies are needed for COVID-19 patients who suffer cytokine storm, which progresses to critical stages of respiratory failure, septic shock, and multiorgan dysfunction. Given that COVID-19 is within the family of RNA viruses, researchers are well positioned to begin development of antiviral therapies, as biochemists already have generated a plethora of molecular information about the atomic structures for the main enzyme required for viral replication, the RNA-dependent RNA polymerase, an enzyme which has no known host counterpart. In this case, biochemists and transcription biologists have already identified Remdesivir, an adenosine nucleotide analog that interferes with the action of viral RNA-dependent RNA polymerase activity. Clinical trials of the drug are currently underway, and early results are encouraging. As for the treatment of cytokine storm, again, basic biochemical research in immunology has paved the way for the development of several therapies, including interleukin-6 (IL-6) inhibitors that function by blocking the IL-6 receptor and ameliorate unwanted damage to tissues and organs caused by cytokine release as the result of viral infection.

The ultimate aim for the treatment of all viral infections, including COVID-19, is the development of host and herd immunity, which can be accomplished either through host infection or vaccination. To manage potential pandemics with the least number of casualties, researchers must develop vaccines that can be mass produced on a scale of hundreds of millions of doses within in a few months after a virus appears and that can be rapidly distributed across the globe. Traditional vaccines use either active or weakened virus or destroyed forms of viral particles as the immune responsegenerating agent. The use of attenuated and destroyed viral particles as vaccines is highly effective, but the manufacturing process is arduous and time-consuming. Recombinant RNA and DNA vaccines circumvent these shortcomings of traditional vaccine generation and are in clinical trial for COVID-19. In this case, humankind owes biochemists Paul Berg, Walter Gilbert, Frederick Sanger, and their colleagues a debt of gratitude for their Nobel prize winning fundamental research in developing recombinant DNA technologies. This work resulted from decades-long funding by U.S. and U.K. governmental agencies and, today, allows the design of recombinant RNA and DNA vaccines and many other life-saving medicines that take advantage of this revolutionary technology.

Once the dust from the COVID-19 pandemic settles and the U.S. Congress is back in session, I hope that lawmakers will recognize our societys dependence on thorough, methodical, mechanistic science and the medicines it provides and ask themselves how many more people might have perished from COVID-19 without the modern methods that arose from the basic molecular research described above. This catastrophe should be a reminder that a healthy investment in all institutes of the NIH and NCI and other federal science agencies will be life-saving when future pandemics arise.

This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial license, which permits use, distribution, and reproduction in any medium, so long as the resultant use is not for commercial advantage and provided the original work is properly cited.

View post:
Medicine in the time of corona: Fundamental molecular research is essential - Science Advances

Alterations that cause skipping of exon 14 on the MET gene (METex14) are drivers of a type of lung cancer with a poor prognosis, but that is treatable with a recently approved MET inhibitor

Foundation Medicine, Inc. and Dana-Farber Cancer Institute presented new data highlighting the utility of comprehensive genomic profiling (CGP) to guide treatment decisions in patients with advanced non-small cell lung cancer (NSCLC) whose tumors also have an alteration that leads to MET exon 14 skipping (METex14). The results underscore the feasibility of tissue and liquid biopsy CGP to characterize common alterations that may be critical for predicting responses to MET inhibitors in patients with NSCLC. These data were presented in a clinical science symposium at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program.

NSCLC accounts for approximately 85% of lung cancer diagnoses, approximately 3% of which have MET exon 14 skipping.1,2 While METex14-altered NSCLC is sensitive to MET inhibition, alterations that co-occur with METex14 may cause treatment resistance to MET inhibitors.

In this analysis of more than 60,000 cases of advanced NSCLC, researchers characterized a subset of 1,387 of patients (2.3%) with METex14-altered NSCLC a prevalence consistent with previous research and identified multiple co-occurring alterations that may cause resistance to MET inhibitors.3,4,5,6 The study also identified six different subclasses of METex14 skipping alterations based on their location, illustrating the complexity of this cancer, which has a poor prognosis.7

"Diverse, co-occurring alterations in METex14 non-small cell lung cancer may correlate with primary or acquired resistance to treatment, so detecting these various alterations using comprehensive genomic profiling may be critical to predicting response to MET inhibitors," said lead study author Mark Awad, M.D., assistant professor of medicine at Harvard Medical School and clinical director of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute. "These data underscore the urgent need to identify effective strategies to delay or overcome resistance to targeted therapies in METex14 mutant NSCLC."

Among 36 patients with paired tissue and liquid samples, potential resistance mechanisms to MET inhibition included 25% of patients with secondary MET alterations, 8% of patients with MET amplification and individual cases with acquired alterations in the EGFR, ERBB2, KRAS and the PI3K pathway were identified. Co-alterations and potential acquired resistance mechanisms appear largely independent of primary METex14 alteration subtype.

"This study emphasizes the importance of comprehensive genomic profiling in patients with METex14-altered NSCLC to facilitate precision medicine both earlier and throughout a patients treatment," said Brian Alexander, M.D., M.P.H, chief medical officer at Foundation Medicine and study co-author. "The study also adds more evidence that genomic testing through both tissue and liquid biopsy can be an important tool for monitoring for resistance alterations during treatment."

A full list of data being presented by Foundation Medicine and its collaborators, and more information about Foundation Medicines portfolio of CGP tests are available at http://comprehensivegenomicprofiling.com.

About METex14-altered Non-Small Cell Lung Cancer

NSCLC accounts for 80-85% of lung cancer diagnoses.1 Mutations that lead to skipping METex14, called skipping alterations, are oncogenic drivers in NSCLC. Approximately 3% of patients with NSCLC have MET exon 14 skipping.2 These tumors produce an altered form of the MET protein, which is a receptor tyrosine kinase that activates a wide range of cellular signaling pathways that can lead to cancer growth.

About Foundation Medicine

Foundation Medicine is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient's unique cancer. The company offers a full suite of comprehensive genomic profiling assays to identify the molecular alterations in a patients cancer and match them with relevant targeted therapies, immunotherapies and clinical trials. Foundation Medicines molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer. For more information, please visit http://www.FoundationMedicine.com or follow Foundation Medicine on Twitter (@FoundationATCG).

Story continues

Foundation Medicine is a registered trademark of Foundation Medicine, Inc.

Source: Foundation Medicine

1 American Cancer Society. About Lung Cancer. Available at https://www.cancer.org/cancer/lung-cancer/about/what-is.html. Accessed May 11, 2020.2 G.M. Frampton, S.M. Ali, M. Rosenzweig, et al.Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors. Cancer Discov, 5 (2015), pp. 850-8593 Characterization of 1,387 NSCLCs with MET exon 14 (METex14) skipping alterations (SA) and potential acquired resistance (AR) mechanisms. Abstract 9511.4 Sadiq AA, Salgia R. MET as a possible target for non-small-cell lung cancer. Journal of Clinical Oncology. 2013;31:1089-1096.5 Smyth EC, et al. Emerging molecular targets in oncology: clinical potential of MET/hepatocyte growth-factor inhibitors. Onco Targets and Therapy. 2014;7:1001-1014.6 Salgia R. MET in Lung Cancer: Biomarker Selection Based on Scientific Rationale. Molecular Cancer Therapeutics. 2017;16(4):555-565.7 Tong JH, et al. MET Amplification and Exon 14 Splice Site Mutation Define Unique Molecular Subgroups of Non-Small Cell Lung Carcinoma with Poor Prognosis. Clin Cancer Res 2016;22:3048-56.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200529005273/en/

Contacts

Lee-Ann Murphy, 617-245-3077pr@foundationmedicine.com

View post:
Foundation Medicine and Dana-Farber Present Data at ASCO20 Showing that Comprehensive Genomic Profiling Identified Co-Occurring Alterations that May...

A recently approved first-in-class antipsychotic appears to have fewer adverse cardiometabolic effects compared with standard care with risperidone, new research suggests.

In post hoc analyses of two short-term randomized controlled trials plus an open-label long-term study, patients with schizophrenia on lumateperone (Caplyta, Intra-Cellular Therapies Inc) had reduced rates of metabolic syndrome compared with their counterparts taking placebo or the antipsychotic risperidone.

In the short-term studies, rates of metabolic syndrome were similar between groups at baseline, but by the end of 4 and 6 weeks of treatment, 25% of patients taking lumateperone no longer met criteria for metabolic syndrome. A similar finding occurred in 36% of patients in the 1-year open label study.

Dr Andrew Satlin

"One of the major advantages that we found during the drug's development was that it has a very favorable profile with regard to changes in weight, and other [parameters] associated with cardiovascular disease risk, such as elevated glucose and lipids," study investigator Andrew Satlin, MD, chief medical officer at Intra-Cellular Therapies, New York City, told Medscape Medical News.

"So we went back to our data and looked to see whether the changes that we saw had an impact on either the development or the resolution of metabolic syndrome in the patients who came into our studies," he said.

The findings were presented at the American Society of Clinical Psychopharmacology (ASCP) 2020 Virtual Conference.

As reported by Medscape Medical News, lumateperone was approved in December by the US Food and Drug Administration (FDA). The drug acts synergistically through the serotonergic, dopaminergic, and glutamatergic systems.

The short-term studies included 511 patients randomly assigned to receive lumateperone 42 mg (n = 256 patients) or risperidone 4 mg (n = 255 patients).

At baseline, rates of metabolic syndrome were 16% in the lumateperone group and 19% in the risperidone group. At the end of treatment, metabolic syndrome was less common in the lumateperone group (13%) vs those receiving risperidone (25%).

In addition, 46% of lumateperone patients with metabolic syndrome at baseline no longer had it at the end of the study period. This compared with 25% of patients on risperidone.

More patients taking risperidone than on lumateperone developed metabolic syndrome during treatment (13% vs 5%).

The differences in metabolic syndrome conversion rates appeared to be driven by greater reductions in total cholesterol with lumateperone compared with risperidone (2.8 mg/dL with lumateperone vs 4.8 mg/dL with risperidone) and triglycerides (0.7 mg/dL with lumateperone vs 20.4 mg/dL with risperidone).

Greater increases in blood glucose were also seen with risperidone (7.7 mg/dL) than with lumateperone (0.9 mg/dL).

The long-term study included 602 patients with stable schizophrenia. All received lumateperone 42 mg, and 197 patients (33%) had metabolic syndrome at baseline.

At the end of the 1-year study, 72 of these patients (36%) no longer met criteria for metabolic syndrome.

"Lumateperone seems to be the safest antipsychotic we have seen so far," Christoph Correll, MD, professor of child and adolescent psychiatry, Charit Universitatsmedizin, Berlin, Germany, who was also involved in clinical trials of lumateperone, told Medscape Medical News.

Dr Christoph Correll

"It seems to be very safe when it comes to cardiometabolic parameters, and it shows similar reduction in symptoms as risperidone. It is certainly an agent one should consider, particularly when a patient cannot tolerate other medications or may not be in full adherence," said Correll, who has a joint appointment as professor of psychiatry and molecular medicine at the Zucker School of Medicine at Hofstra/Northwell in Hempstead, New York.

The drug's safety and efficacy profile would make it a good candidate in patients initiating antipsychotic treatment, but reimbursement issues may be a barrier, at least for now, he added.

He said that the drug may prevent the onset of metabolic side effects and added that once payers are willing to reimburse the drug it should become the "first-line standard of care."

It is well known that atypical antipsychotics are associated with adverse and rapid metabolic changes. Correll noted that particularly early-phase and first-episode patients can be "very sensitive" to the side effects of these drugs and often experience rapid weight gain and other adverse metabolic changes. Lumateperone, he added, may help avoid some of this cardiometabolic risk.

Commenting on the findings for Medscape Medical News, Jessica M. Gannon, MD, a psychiatrist at the University of Pittsburgh in Pennsylvania, said the drug's favorable metabolic profile has previously been reported.

She also noted that there has been some interest in lumateperone due to possible "downstream effects on NMDA-type glutamate receptor activity, a larger binding ratio at D2:5HT1A receptors than other atypical antipsychotics, and presynaptic D2 partial agonism and a postsynaptic D2 antagonism."

"This latter feature may explain the reported low extrapyramidal symptom incidence in the clinical trials," she said .

"While I think future studies and clinical use can help determine how clinically efficacious this medication will be for our patients when compared to others on the market, its favorable metabolic and EPS profile do make it of interest," added Gannon, who was not involved in researching the drug.

The study was funded by Intra-Cellular Therapies. Satlin is chief medical officer of Intracellular Therapies. Correll has been a consultant or advisor to and has received honoraria from Acadia, Alkermes, Allergan, Angelini, Axsome, Gedeon Richter, Gerson Lehrman Group, Intra-Cellular Therapies, Janssen/J&J, LB Pharma, Lundbeck, MedAvante-ProPhase, Medscape, Neurocrine, Noven, Otsuka, Pfizer, Recordati, Rovi, Sumitomo Dainippon, Sunovion, Supernus, Takeda, and Teva.

American Society of Clinical Psychopharmacology (ASCP) 2020: Abstract 3002348. Presented May 30, 2020.

For more Medscape Psychiatry news, join us on Facebook and Twitter

Read the original here:
First-in-Class Antipsychotic Linked to Lower Cardiometabolic Risk - Medscape

SAINT-PREX, Switzerland & VALENCIA, Spain--(BUSINESS WIRE)--Ferring Pharmaceuticals and Igenomix today announced a two-year research collaboration aimed at the discovery of novel targets and disease mechanisms in infertility and pregnancy-related conditions, including preeclampsia, with the goal of developing innovative diagnostic and therapeutic strategies in these areas of high unmet need.

A new research hub will be created in Boston, bringing together scientists and expertise from both companies. The hub will focus on investigating molecular signatures, developing novel functional genomic systems and creating translational tools to study for embryo implantation, endometrial microbiome interaction and decidualization biology to drive innovative solutions for patients.

Today, 1 in 6 couples worldwide are affected by fertility issues, with embryo implantation being a critical step to improving success rates in assisted reproduction technologies (ART) such as IVF. Furthermore, between 3 and 5% of all pregnancies are affected by preeclampsia,1 a severe complication which increases the morbidity and mortality of both mother and baby, said Joan-Carles Arce, Senior Vice President of Reproductive Medicine and Maternal Health, Ferring. Through this collaboration, we aim to advance diagnostic testing and the discovery of candidate drug targets in these areas of high unmet need and ultimately help more people build healthy families worldwide.

This new research hub will connect Igenomixs unique diagnostic capabilities with Ferrings deep therapeutic expertise, said Professor Carlos Simn, Head of Scientific Board of Igenomix Foundation and Project Lead for the new hub. We believe this collaboration will accelerate scientific findings and improve conception rates at a time when significant progress is needed in preimplantation science to help more women and families experience healthy pregnancies.

ENDS

About Fertility Issues

The World Health Organization defines infertility as a disease of the reproductive system defined by the failure to achieve a clinical pregnancy after 12 months or more of regular unprotected sexual intercourse. Today, 1 in 6 couples worldwide are affected by fertility issues. Assisted Reproductive Technologies (ART) such as In Vitro Fertilisation (IVF) and Intracytoplasmic Sperm Injection (ICSI) can help couples who have problems conceiving naturally.

About Preeclampsia

Preeclampsia is a common and severe complication of pregnancy characterised by high blood pressure and multiple organ failure. It affects between 3% and 5% of all pregnancies in the US.1 There is a significant unmet need for an effective treatment for preeclampsia; currently the only treatment is delivery of the baby.

Preeclampsia is responsible for approximately 20% of all preterm births2 and increases the morbidity and mortality of both mother and baby, especially in developing countries. An effective treatment would bring significant improvements in global infant and maternal health.

About Ferring Pharmaceuticals

Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group committed to helping people around the world build families and live better lives. Headquartered in Saint-Prex, Switzerland, Ferring is a leader in reproductive medicine and maternal health, and in specialty areas within gastroenterology and urology. Ferring has been developing treatments for mothers and babies for over 50 years and has a portfolio covering treatments from conception to birth. Founded in 1950, privately-owned Ferring now employs approximately 6,500 people worldwide, has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries.

Learn more at http://www.ferring.com, or connect with us on Twitter, Facebook, Instagram, LinkedIn and YouTube.

About Igenomix

Igenomix is a biotech company based in Valencia, Spain, specialized in reproductive genetics. Its expertise in fertility and its advanced research capacity situates the company as a worldwide referent in this area. Igenomix has 23 laboratories across the world and employs more than 400 professionals. Since the company launch in 2010, Igenomix has published more than 450 scientific papers and its communications have taken place during high level congresses such as ESHRE (European Society of Human Reproduction) or ASRM (American Society for Reproductive Medicine). Igenomix researchers have received numerous awards recognizing research and many of them share their knowledge and knowhow in leading US universities such as Stanford or Harvard.

References:

# # #

See original here:
Ferring and Igenomix Collaborate to Advance Care in Reproductive Medicine and Maternal Health - Business Wire

Structural Biology and Molecular Modeling Techniques Market: Overview

The global structural biology and molecular modeling techniques market is a novel conception in the global healthcare sector and has already made key contributions in obtaining remedies to a number of diseases. The structural biology and molecular modeling field is concerned with how various molecules in biological compounds are arranged and how the peculiarity of the arrangement affects the nature of the compound. The field also studies how alterations in the structure of the compounds affect their nature and how the position of each part of the structure is linked to the overall nature of the compound.

Get Exclusive PDF Sample Copy Of This Report:https://www.tmrresearch.com/sample/sample?flag=B&rep_id=1280

The structural biology and molecular modeling techniques market has significant potential due to the rising prevalence of chronic diseases. Improving the quality of medicine and healthcare in general has been a key focus of governments across the world in recent years due to the rising volume of patient demographics and the growing geriatric population. This has driven consistent investment in the medical research in recent years, making steady development of the structural biology and molecular modeling techniques market likely in the near future.

North America is likely to remain the leading regional market for structural biology and molecular modeling techniques in the coming years due to the strong emphasis on the widespread incorporation of healthcare IT and the presence of strong investment channels for the medical research field as well as several key healthcare industry players. The presence of advanced technological framework supporting research in complementary areas of the structural biology and molecular modeling techniques market, such as genomics, is also likely to be a key driver for the North America structural biology and molecular modeling techniques market in the coming years.

Global Structural Biology and Molecular Modeling Techniques Market: Snapshot

The global structural biology and molecular modeling techniques market has been thriving due to the high prevalence of chronic diseases. The market is also gaining a strong foothold across the globe as treating these diseases is becoming increasingly difficult due to the acquired drug resistance. In the light of these developments, research and development activities using structural biology and molecular modeling techniques have been in full swing. The increasing focus on improving the quality of medicines and ensuring patient recovery and safety has augmented the demand for various structural biology and molecular modeling techniques. The demand for these techniques is projected to soar as the need to reduce drug failure is an immense one amongst healthcare institutes.

The report answers questions pertaining to the size of the global market by the end of the forecast period, leading segments, and players amongst others. The report is a comprehensive outlook of the global market and it presents key market insights for readers with absolute objectivity.

Global Structural Biology and Molecular Modeling Techniques Market: Drivers and Trends

The rapid pace of technological developments and innovations have been exceptionally supportive of the global market over the past few years. Both these aspects have authenticated the sophisticated models that help in the accurate determination of cellular interactions and function, which in turn helps in identifying the problem area and a subsequent solution. The wide range of structural biology and molecular modeling techniques are expected to find tremendous scope in the area of drug discovery. These techniques will prove to be important in identifying the missing pieces that limit the process of drug discovery, thereby resulting in high success rates.

Adoption of these techniques in pharmacogenomics and pharmacogenetics are also expected to prove beneficial to the overall growth of the market. Analysts project that increasing incidences of diseases where several drugs cannot be administered to the patient will prove to be a lucrative ground for the global structural biology and molecular modeling techniques market.

Buy This Report @https://www.tmrresearch.com/checkout?rep_id=1280<ype=S

Global Structural Biology and Molecular Modeling Techniques Market: Regional Outlook

Spread over regions such as North America, Asia Pacific, the Middle East and Africa, Europe, and Latin America, the global structural biology and molecular modeling techniques market has truly made its market in North America. The higher understanding of diseases and empathy toward managing them with supportive regulatory policies has been North Americas winning strategy for the past few years. Increasing funding for research and development of novel drugs is expected to favor this regional markets growth in the coming years as well.

On the other hand, increasing expenditure on IT, healthcare infrastructure, and research organizations in Asia Pacific is also expected to open up new avenues for growth for the overall market. Furthermore, the rising standard of living of people in developing countries, improving GDPs, and better access to healthcare are also expected to fuel the demand for structural biology and molecular modeling techniques in Asia Pacific.

Global Structural Biology and Molecular Modeling Techniques Market: Competitive Landscape

The key players identified by the research analysts are Dassault Systemes, Agile Molecule, Acellera Ltd., Bioinformatic LLC, Affymetrix, Agilent Technologies, Inc., Illumina, Bruker Daltonics Inc., Biomax Informatics AG, Chemical Computing Group, and CLC bio. The report points out that the global market is expected to witness intense competition in the coming years. However, to stay ahead of the competition, several players are expected to focus on mergers and acquisitions, investments for novel drug development, and technological advancements.

To know more about the table of contents, you can click @https://www.tmrresearch.com/sample/sample?flag=T&rep_id=1280

About TMR Research

TMR Research is a premier provider of customized market research and consulting services to busi-ness entities keen on succeeding in todays supercharged economic climate. Armed with an experi-enced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

The rest is here:
Structural Biology and Molecular Modeling Techniques Market Size, Application, Region and Growth Forecast 2017-2025 - 3rd Watch News